8:00 am
8:30 am
Dawn Holcombe
Dawn Holcombe
Director
NAMCP Medical Directors Institute Oncology Council

8:40 am

Precision medicine offers unprecedented promise for the treatment of cancer, including creating personalized approaches to care based on each patient’s personal genetic makeup. While the clinical opportunities are tremendous, harnessing the potential of precision medicine presents significant challenges, from educating patients and physicians to building the necessary infrastructure to support data management and information sharing. Learn how one of the leading non-profit health systems in the U.S. is working to overcome these challenges and create an integrated precision medicine program to improve patient outcomes.

  • Explore how precision medicine is transforming the treatment of oncology, from informing and accelerating clinical decisions to improving outcomes
  • Understand the critical role of AI in the advancement of precision medicine
  • Discuss the five critical components for the successful development and implementation of a precision medicine program
  • Learn how to educate both providers and patients on the value of precision medicine, and in an efficient manner as it continues to evolve
Douglas Reding
Douglas Reding, MD, MPH, FACP
Chief Medical Officer
Ascension Wisconsin

9:20 am

The Oncology Care Model aims to deliver high-quality and high-value cancer care. Since performance on the quality measures can impact payments received, participants must implement qualitative and quantitative strategies to reach the benchmarks of the episode of care. The complexity and diversity of clinical cancer care creates challenges for those participating in this model. In this session, review the policies and regulations associated with OCM, discuss the current landscape and how to balance invested resources and potential savings that could be generated.

  • Analyze the current performance and assess if it can scaled to further achieve quality measures and benchmarks
  • Outline necessary parameters and resources needed to participate
  • Hear best practices and lessons learned from organizations that are already in this model
Sarah Cevallos
Sarah Cevallos
Chief Revenue Cycle Officer
Florida Cancer Specialists
Chief Revenue Cycle Officer
American Oncology Partners, P.A.

10:00 am

Health care organization often participate in multiple risk-based agreements in oncology care. Since risk-based agreements are often heavily impacted by the performance of primary care physicians, not having PCPs as part of a health care organization makes is harder for providers to get into risk-based contracts. Challenges also appear when patients treated are part of multiple existing contracted agreements. In this session, discuss the intricacies of operating and administering risk-based models in a health care organization.

  • Determine your organization’s readiness for two-sided risk and value-based care
  • Discuss key foundational organizational and leadership competencies, and resources that a hospital/practice needs to put in place in order to prepare for value-based payment models that will be coming in the future
Nikolas Buescher
Nikolas Buescher
Executive Director, Cancer Services
Penn Medicine Lancaster General Health

11:10 am

CAR T-cell therapy is an emerging form of cellular therapy that is rapidly changing cancer treatment for hematologic malignancies, and emerging in the treatment of solid tumors. There are significant challenges in both clinical, business, payer, and operational logistics to be considered before adopting this therapy. In this session, hear how UChicago Medicine leveraged its first-to-market advantage in adopting this groundbreaking treatment, and gain an appreciation of the numerous resources needed to implement and administer CAR-T Cell therapy in your organization.

  • Learn how to make the business case for the adoption of CAR T-cell Therapy
  • Understand the strategic and operational considerations in adopting CAR T-cell Therapy
Luca Capicchioni
Luca Capicchioni
Program Manager for Stem Cell Transplant and Cellular Therapy
UChicago Medicine

Tony Navarra
Tony Navarra
Director, Managed Care Contracting & Finance
The University of Chicago Medicine

11:50 am

The prevalence of high out-of-pockets costs for cancer treatments creates financial distress on patients and their families. This not only creates financial hardships but also impacts patient outcomes as it can affect their adherence with medications and the decision to opt out of more expensive yet effective treatments. In this session, discuss the issues related to financial toxicity and initiatives that can be implemented.

  • Review current status and the main causes of financial toxicity
  • Analyze data that speaks to challenges in cancer patient journey
  • Uncover short-term and long-term strategies that stakeholders can adapt to mitigate financial burden on patients
Dawn Holcombe
Dawn Holcombe
Director
NAMCP Medical Directors Institute Oncology Council

12:30 pm